374 related articles for article (PubMed ID: 25173912)
1. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
He CJ; Chen SJ; Wang J; Zhu CY; Yin YH
Pulm Pharmacol Ther; 2015 Jun; 32():24-8. PubMed ID: 25843006
[TBL] [Abstract][Full Text] [Related]
4. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis.
Zhu B; Wang L; Sun L; Cao R
J Cardiovasc Pharmacol; 2012 Oct; 60(4):342-6. PubMed ID: 22691882
[TBL] [Abstract][Full Text] [Related]
6. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy in pulmonary arterial hypertension: a meta-analysis.
Bai Y; Sun L; Hu S; Wei Y
Cardiology; 2011; 120(3):157-65. PubMed ID: 22212696
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Petrovič M; Locatelli I
Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
[No Abstract] [Full Text] [Related]
9. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
[TBL] [Abstract][Full Text] [Related]
10. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
11. [Targeted therapy of pulmonary arterial hypertension (PAH)].
Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
[No Abstract] [Full Text] [Related]
12. Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis.
Badiani B; Messori A
Heart Lung Circ; 2016 Jan; 25(1):46-52. PubMed ID: 26233257
[TBL] [Abstract][Full Text] [Related]
13. Gender-related differences in pulmonary arterial hypertension targeted drugs administration.
Marra AM; Benjamin N; Eichstaedt C; Salzano A; Arcopinto M; Gargani L; D Alto M; Argiento P; Falsetti L; Di Giosia P; Isidori AM; Ferrara F; Bossone E; Cittadini A; Grünig E
Pharmacol Res; 2016 Dec; 114():103-109. PubMed ID: 27771466
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis.
Zhang HD; Zhang R; Jiang X; Sun K; Wu DC; Jing ZC
Am Heart J; 2015 Jul; 170(1):96-103, 103.e1-14. PubMed ID: 26093869
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.
Ryerson CJ; Nayar S; Swiston JR; Sin DD
Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497
[TBL] [Abstract][Full Text] [Related]
16. Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials.
Gao XF; Zhang JJ; Jiang XM; Ge Z; Wang ZM; Li B; Mao WX; Chen SL
Patient Prefer Adherence; 2017; 11():871-885. PubMed ID: 28507431
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
19. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.
Zheng Y; Yang T; Chen G; Hu E; Gu Q; Xiong C
Eur J Clin Pharmacol; 2014 Jan; 70(1):13-21. PubMed ID: 24026627
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.
Lajoie AC; Lauzière G; Lega JC; Lacasse Y; Martin S; Simard S; Bonnet S; Provencher S
Lancet Respir Med; 2016 Apr; 4(4):291-305. PubMed ID: 26935844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
